Serge Gauthier
6825, Boulevard Lasalle
Montréal, QC
H4H 1R3
C.M., MD, FRCPC
Alzheimer's Disease Research
Alzheimer Disease Research Unit
Randomized clinical trials for MCI and AD
Trial designs and outcomes development, with emphasis on non-cognitive domains (ADL and behavior).
Wu L, Rosa-Neto P, Hsiung GYR, Sadovnick AD, Masellis M, Black SE, Jia J, Gauthier S. Early-onset Familial Alzheimer’s Disease (EOFAD). Canadian Journal of Neurological Sciences, 39, 436-445, 2012.
Gauthier S, Patterson C, Chertkow H, Gordon M, Herrmann N, Rockwood K, Rosa-Neto P, Soucy JP on behalf of the CCCDTD4 participants. Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Canadian Journal of Geriatrics, 15, 120-126, 2012.
Gauthier S, Molinuevo J. Benefits of combination treatment in Alzheimer’s disease. Alzheimer’s & Dementia, 9, 326-331, 2013.
Dubois B, Gauthier S, Cummings J. The utility of the new research criteria for Alzheimer’s disease. International Psychogeriatrics, 25, 174-184, 2013.
Gauthier S, Leuzy A, Racine E, Rosa-Neto P. Diagnosis and management of Alzheimer’s disease: past, present and future ethical issues. Progress in Neurobiology, 110, 102-113, 2013.
Rowley J, Fonov V, Wu O, eskildsen S, Scoemaker D, Wu L, Mohades S, Shin M, Sziklas V, Shmuel A, Dagher A, Gauthier S, Rosa-Neto P and the Alzheimer’s Disease Neuroimaging Initiative. White matter abnormalities and structural hippocampal disconnections in AD, naMCI and aMCI. PloS ONE, 8, e74776, 2013.
Gauthier S, Leuzy A, Rosa-Neto P. How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer’s disease? Neurodegenerative Diseases, 13, 197-199, 2014.
Dubois B, Feldman HH, Jacova C, Hampel H, Moniluevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Cappa S, Crutch S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberd A, Pasquier F, Rabinovivi G, Robert P, Rowe C, Salloway S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. Improving diagnostic criteria for Alzheimer’s disease – an update from the International Working Group. Lancet Neurology, 13, 614-629, 2014.
Wu L, Soder RB, Shoemaker D, Carbonell F, Sziklas V, Rowley J, Mohades S, Fonov V, Bellec P, Dagher A, Sziklas V, Schmuel A, Jia J, Gauthier S, Rosa-Neto P. Resting state executive control network adaptations in amnestic mild cognitive impairment. Journal of Alzheimer Disease, 40, 993-1004, 2014.
Zimmer ER, Leuzy A, Bhat V, Gauthier S, Rosa-Neto P. In vivo tracking of tau pathology using PET molecular imaging in small animals. Translational Neurodegeneration, 3, 6, 2014.
Hye A, Riddoch-Contreras J, Baird AL, Ashton NJ, Bazenet C, Leung R, Westman E, Simmons A, Dobson R, Sattlecker M, Lupton M, Lunnon K, Keohane A, Ward M, Pike I, Zucht HD, Pepin D, Zheng W, Tunnicliffe A, Richardson J, Gauthier S, Soininen H, Kloszewska I, Mecocci P, Tsoalki M, Vellas B, Lovestone S. Plasma proteins predict conversion to dementia from prodromal disease. Alzheimer’s & Dementia, 10, 799-807, 2014.
Vellas B, Sampaio C, Bateman R, Boxer A, Carrillo MC, Cummings J, Dubois B, Hampel H, Katz R, Khachaturian Z, Gauthier S, Johnson K, Karlawish J, Mintun M, Petersen R, Rafii M, Robert P, Schneider LS, Siemers E, Sperling R, Tariot P, Touchon J, Weiner M, Andrieu S, Aisen P and Task Force Members. E.U./U.S. Task Force on Alzheimer’s Trial populations. Journal of Prevention of Alzheimer’s Disease, 1, 110-116, 2014.
Cummings J, Mintzer J, Brodaty H, Sano M, Banerjee S, Cohn-Mansfield J, Devanand DP, Gauthier S, Howard R, Lanctot K, Lyketsos K, Peskind E, Porsteinsson A, Reich E, Ryan L, Simpaio C, Schneider L, Steffens D, Thies W, Wortman M, Zhong K for the IPA Agitation Definition Working Group. Agitation in cognitive disorders: IPA provisional consensus clinical and research definition. International Psychogeriatrics, 27, 7-17, 2015.
Gauthier S, Dubois B, Poirier J, Leuzy A, Rosa-Neto P. Le diagnostic précoce de la maladie d’Alzheimer : panacée ou catastrophe? Ethics, Medicine and Public Health: a multidisciplinary journal, in press
Medical studies at Université de Montréal, Neurology training at McGill University, Research Fellowship at Prof. Theodore L. Sourkes laboratory, Allen Memorial Institute, Montreal. Clinical investigator and staff neurologist at the Montreal Neurological Hospital and Institute (1976-1986), Director of the McGill Centre for Studies in Aging (1886-1996), Senior Scientist of the CIHR-Rx&D program (1997-2007). Currently Professor in the Departments of Neurology & Neurosurgery, Psychiatry, Medicine, at McGill University, and Director of the Alzheimer Disease and Related Disorders Research Unit of the McGill Center for Studies in Aging, Douglas Hospital. Contributions to research include design and implementation of randomized clinical trials in order to establish the safety and efficacy of cholinesterase inhibitors, muscarinic agonists, and agents possibly modifying progression for Alzheimer’s disease and vascular dementia. Special interests include consensus approach to the management of dementia in different stages, the ethics of research involving persons with dementia, and primary prevention strategies against cognitive decline and dementia.
1997 Prix Galien, PMAC, with Drs. J. Poirier and R. Quirion
1998 CCNP Innovations in Neuropsychopharmacology Award, with Drs. J. Poirier and R. Quirion
2000 Médaille ‘Médecin de Mérite’ de l’Actualité Médicale
2005 Prix de l’oeuvre scientifique, Association des médecins de langue française du Canada
2006 Prix ‘Ambassadeur’ du Palais des Congrès de Montréal
2007 Elected member of « Best Doctors », North America
2009 Prix d’excellence du Collège Royal des Médecins et Chirurgiens du Canada
2009 Irma Parhad Award, Consortium of Canadian Centers for Clinical Cognitive Research
2012 Prix Hubert Reeves de l’Association des communicateurs scientifiques du Québec pour la valorization d’ouvrages scientifiques grand public avec Dr J. Poirier
2014 Médaille du jubilé de diamant de la reine Elizabeth II
2014 Membre de l’Ordre du Canada (C.M.)
Drs Pedro Rosa-Neto, Stéphane Ledoux, Marie-Chantal Ménard , Paolo Vitelli
In the news
Recent Publications
-
Brain perfusion during rapid-eye-movement sleep successfully identifies amnestic mild cognitive impairment. Sleep Med. 2017;34:134-140.
-
Application of calibrated fMRI in Alzheimer's disease. Neuroimage Clin. 2017;15:348-358.
-
Consensus-based recommendations for the management of rapid cognitive decline due to Alzheimer's disease. Alzheimers Dement. 2017;13(5):592-597.
-
Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain. Alzheimers Res Ther. 2017;9(1):25.
-
Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. Neurology. 2017;88(19):1814-1821.
-
Family history and APOE4 risk for Alzheimer's disease impact the neural correlates of episodic memory by early midlife. Neuroimage Clin. 2017;14:760-774.
-
Research update on Alzheimer's disease and introduction to the Expert Review of Neurotherapeutics special issue. Expert Rev Neurother. 2017;17(1):1-2.
-
The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations. J Alzheimers Dis. 2017;56(3):929-938.
-
Synergistic interaction between amyloid and tau predicts the progression to dementia. Alzheimers Dement. 2017;13(6):644-653.
-
[(18)F]FDG PET signal is driven by astroglial glutamate transport. Nat Neurosci. 2017;20(3):393-395.
-
Multicenter Validation of an MMSE-MoCA Conversion Table. J Am Geriatr Soc. 2017;65(5):1067-1072.
-
VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis. Front Neuroinform. 2016;10:20.
-
Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients. Continuum (Minneap Minn). 2016;22(2 Dementia):615-8.
-
Why has therapy development for dementia failed in the last two decades? Alzheimers Dement. 2016;12(1):60-4.
-
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3):292-323.
-
Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurol. 2016;15(5):455-532.
-
Selective familiarity deficits in otherwise cognitively intact aging individuals with genetic risk for Alzheimer's disease. Alzheimers Dement (Amst). 2016;2:132-9.
-
Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease? Transl Neurodegener. 2016;5:20.
